tbuckley/cabot-search huggingface dataset:
Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies
Authors: Saurabh Chhabra, Natalie S. Callander, Luciano J. Costa, Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Larry D. Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Bhagirathbhai Dholaria, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees
Journal: Blood (2021)
Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment
Authors: Tracy L. Hagemann, Berit Powers, Ni-Hsuan Lin, Ahmed F. Mohamed, Katerina L. Dague, Seth C. Hannah, Gemma Bachmann, Curt Mazur, Frank Rigo, Abby L. Olsen, Mel B. Feany, Ming-Der Perng, Robert F. Berman, Albee Messing
Journal: Science Translational Medicine (2021)

Gfap -antisense prevents disease with early treatment and reverses clinical phenotypes with late treatment in a rat model of Alexander disease.
RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance
Authors: Vincent Javaugue, Virginie Pascal, Sébastien Bender, Sarah Nasraddine, Mathilde Dargelos, Mehdi Alizadeh, Alexis Saintamand, Matthieu Filloux, Paco Derouault, Sabrina Bouyer, Estelle Desport, Arnaud Jaccard, Frank Bridoux, Michel Cogné, Christophe Sirac
Journal: Kidney International (2021)
Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)
Authors: Guillermo Garcia-Manero, Harry P. Erba, Srinivasa R. Sanikommu, Jessica K. Altman, Hamid Sayar, Bart L. Scott, Abraham P. Fong, Shanhong Guan, Feng Jin, Alison J. Forgie, Jaume Pons, Sophia S. Randolph, Michael T. Byrne
Journal: Blood (2021)
A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies
Authors: Felipe Samaniego, John M. Burke, Daruka Mahadevan, Mohamad Cherry, Ahad A. Sadiq, M. Zach Koontz, Jose C. Villasboas, Erin Reid, Elizabeth Cull, Victor Priego, Lindsey E. Roeker, Patrick Cobb, Jason Melear, Paul Conkling, David Cosgrove, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Donna Nguyen Haney, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar
Journal: Blood (2021)
Abstract 9323: Molecular Defects Are Not Associated With Occurrence of Cardiovascular Events in Older Individuals With Familial Hypercholesterolemia on Lipid Lowering Therapy
Authors: Elaine Coutinho, Marcio H Miname, Viviane Z Rocha, Marcio S Bittencourt, CInthia Jannes, Alexandre Pereira, Jose Krieger, Raul D Santos
Journal: Circulation (2021)

Introduction: Familial hypercholesterolemia (FH) is a genetic disorder associated with early onset atherosclerotic cardiovascular disease (ASCVD). However, lipid lowering therapies (LLT) may change FH natural history. There is scant data about elderly (≥60 years) with FH. Hypothesis: FH molecular defect may not influence on ASCVD risk after LLT in older individuals. Methods: Older hypercholesterolemic individuals were divided into 4 groups (2X2) according to the presence (FH +) or not of genetic variants (FH-) and previous or not clinical ASCVD (ASCVD+ and ASCVD-). Association of biomarkers with ASCVD onset was tested using Cox models. Results: From 4,111 genotyped individuals, 377 (9.1%) were elderly [age 66 (63; 71)] years, 28.9% men, 42.7% FH+, LDL-C on LLT 144 (109; 200) mg/dL, median LLT duration 9 (5;16) years. Overall ASCVD was present in 32.1%, and 62.1% and 34.5% had ASCVD of early onset in FH+ and FH- respectively. FH-/ASCVD+ (n=161), FH+/ASCVD- (n=95), FH-/ASCVD+ (n=55) and FH+/ASCVD+(n=66) were followed by 4.8(7;3) years and 51 new ASCVD events (2.8/100 patients/year) occurred. No differences were seen regarding age, hypertension, body mass index, current use, duration, and intensity of LLT and LDL-C at the last follow-up visit. In univariate analysis there was an association of male gender (p = 0.002), presence of genetic variants (p = 0.006), diabetes (p = 0.006), smoking (p = 0.028) and previous ASCVD (p = 0.000) with new ASCVD event. There was no association of LLT and current or previous lipid profile, except with HDL-C at diagnosis (p=0.014), with ASCVD event. Table 1 shows that after multivariate analysis the genetic defect was not associated with occurrence of ASCVD events. Conclusion: Although FH is associated with a higher risk of early ASCVD even when compared to other hypercholesterolemics, in older individuals after LLT the presence of genetic defects was not associated with the occurrence of new events.
Abstract 12761: Association of Medical Non-Adherence to Health Status Outcomes in the ISCHEMIA Trial
Authors: R. Angel Garcia, John Spertus, Philip Jones, Daniel B Mark, Jonathan D Newman, Sripal Bangalore, William E Boden, Gregg W Stone, Harmony Reynolds, Judith S Hochman, David J Maron
Journal: Circulation (2021)

Introduction: In the ISCHEMIA trial, participants managed invasively (INV; guideline-directed medical therapy [GDMT] + angiography ± revascularization) had better health status outcomes than those managed conservatively (CON; GDMT alone). It is unknown whether adherence to prescribed medications affects health status outcomes in chronic coronary disease (CCD). Hypothesis: Patient-reported medication non-adherence more adversely impacts health status outcomes in those treated with a CON, but not an INV, strategy. Methods: Self-reported adherence was assessed at randomization with a modified Morisky-Green-Levine medication adherence measure and patients were dichotomized into adherent (never skipping meds) and non-adherent (occasionally skipping meds). Twelve-month health status outcomes were assessed with the 7-item Seattle Angina Questionnaire (SAQ) Summary Score (SS; range 0-100, higher = better) using adjusted mixed effects cumulative probability models within a Bayesian framework to estimate differences between adherent and non-adherent patients, stratified by study arm. Results: Among 4480 randomized patients in the SAQ cohort, 1245 (27.8%) reported non-adherence at baseline. These patients had worse SAQ scores at baseline (CON: 72.9 ± 19.3 vs. 75.6 ± 18.4; INV: 71.0 ± 19.8 vs. 74.2 ± 18.7) and follow-up (CON: 81.2 ± 18.3 vs. 85.4 ± 15.0; INV: 84.3 ± 17.4 vs. 88.2 ± 13.9). The Figure shows similar posterior distributions of better SAQ scores with adherence in both arms (Mean difference = 1.63 (95% CrI 0.33, 2.89) in CON; 1.93 (95% CrI 0.80, 3.06) in INV). Conclusions: Medication non-adherence—as was reported in over 1 in 4 patients—was associated with worse 12-month health status, an effect that was similar in CON and INV strategies. While causation cannot be established, improving adherence may improve health status outcomes in CCD, regardless of treatment strategy.
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
Authors: Shun Lu, Qiming Wang, Guojun Zhang, Xiaorong Dong, Cheng-Ta Yang, Yong Song, Gee-Chen Chang, You Lu, Hongming Pan, Chao-Hua Chiu, Zhehai Wang, Jifeng Feng, Jianying Zhou, Xingxiang Xu, Renhua Guo, Jianhua Chen, Haihua Yang, Yuan Chen, Zhuang Yu, Her-Shyong Shiah, Chin-Chou Wang, Nong Yang, Jian Fang, Ping Wang, Kai Wang, Yanping Hu, Jianxing He, Ziping Wang, Jianhua Shi, Shaoshui Chen, Qiong Wu, Changan Sun, Chuan Li, Hongying Wei, Ying Cheng, Wu-Chou Su, Te-Chun Hsia, Jiuwei Cui, Yuping Sun, Sai-Hong Ignatius Ou, Viola W. Zhu, James Chih-Hsin Yang
Journal: Journal of Thoracic Oncology (2021)

Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) with revealed activity against EGFR-sensitizing mutations and EGFR T790M mutation.Patients with locally advanced or metastatic NSCLC who developed an EGFR T790M mutation after progression on first- or second-generation EGFR TKI therapy were enrolled in this registrational phase 2 trial of aumolertinib at 110 mg orally once daily (NCT02981108). The primary end point was objective response rate (ORR) by independent central review.A total of 244 patients with EGFR T790M-positive NSCLC were enrolled. The ORR by independent central review was 68.9% (95% confidence interval [CI]: 62.6-74.6). The disease control rate was 93.4% (95% CI: 89.6-96.2). The median duration of response was 15.1 months (95% CI: 12.5-16.6). The median progression-free survival was 12.4 months (95% CI: 9.7-15.0). Among 23 patients with assessable central nervous system (CNS) metastases, the CNS-ORR and CNS-disease control rate were 60.9% (95% CI: 38.5-80.3) and 91.3% (95% CI: 72.0-98.9), respectively. The median CNS-duration of response was 12.5 months (95% CI: 5.6-not reached). Treatment-related adverse events of more than or equal to grade 3 occurred in 16.4% of the patients, with the most common being increased blood creatine phosphokinase level (7%) and increased alanine aminotransferase level (1.2%). The relative dose density of aumolertinib was 99.2% in this study.Aumolertinib is an effective and well-tolerated third-generation EGFR TKI for patients with EGFR T790M-positive advanced NSCLC after disease progression on first- and second-generation EGFR TKI therapy. On the basis of these findings, aumolertinib was approved in the People's Republic of China for patients positive for EGFR T790M NSCLC.
Functional Multi-Omics Reveals Genetic and Pharmacologic Regulation of Surface CD38 in Multiple Myeloma
Authors: Priya Choudhry, Olivia Gugliemini, Huimin Geng, Vishesh Sarin, Letitia Sarah, Yu-Hsiu T. Lin, Neha Paranjape, Poornima Ramkumar, Makeba Marcoulis, Donghui Wang, Paul Phojanakong, Veronica Steri, Byron Hann, Martin Kampmann, Arun P Wiita
Journal: Blood (2021)
Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome
Authors: Marcella Kaddoura, Moritz Binder, David Dingli, Francis K. Buadi, Martha Q. Lacy, Morie A. Gertz, Angela Dispenzieri, Prashant Kapoor, Yi L. Hwa, Amie Fonder, Miriam A. Hobbs, Suzanne R. Hayman, Nelson Leung, Ronald Go, Yi Lin, Wilson I Gonsalves, Taxiarchis Kourelis, Rahma M Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar
Journal: Blood (2021)
Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL)
Authors: Nicola C Maciocia, Amy Burley, Francesco Nannini, Patrycja Wawrzyniecka, Margarida Neves, Thaneswari Karpanasamy, Mathieu Ferrari, Teresa Marafioti, Shimobi Onuoha, Asim Khwaja, Paul M Maciocia, Martin Pule
Journal: Blood (2021)
Neocortex saves energy by reducing coding precision during food scarcity
Authors: Zahid Padamsey, Danai Katsanevaki, Nathalie Dupuy, Nathalie L. Rochefort
Journal: Neuron (2021)

Information processing is energetically expensive. In the mammalian brain, it is unclear how information coding and energy use are regulated during food scarcity. Using whole-cell recordings and two-photon imaging in layer 2/3 mouse visual cortex, we found that food restriction reduced AMPA receptor conductance, reducing synaptic ATP use by 29%. Neuronal excitability was nonetheless preserved by a compensatory increase in input resistance and a depolarized resting potential. Consequently, neurons spiked at similar rates as controls but spent less ATP on underlying excitatory currents. This energy-saving strategy had a cost because it amplified the variability of visually-evoked subthreshold responses, leading to a 32% broadening of orientation tuning and impaired fine visual discrimination. This reduction in coding precision was associated with reduced levels of the fat mass-regulated hormone leptin and was restored by exogenous leptin supplementation. Our findings reveal that metabolic state dynamically regulates the energy spent on coding precision in neocortex.
Romiplostim for the Treatment of Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia: Subgroup Analysis from a Phase 2 Study
Authors: Adrian C. Newland, Jean-Francois Viallard, María Fernanda López Fernández, Melissa Jeanne Eisen, Hossam A Saad, Jane Hippenmeyer, Bertrand Godeau
Journal: Blood (2021)
Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group
Authors: Charles Herbaux, Caroline Bret, Roberta Di Blasi, Emmanuel Bachy, David Beauvais, Elodie Gat, Thomas Gastinne, Florence Broussais, Guillaume Cartron, Alexis Cuffel, Loic Ysebaert, Mikael Roussel, Krimo Bouabdallah, Julien Guy, Arnaud Campidelli, François Van Laethem, Rene-Olivier Casasnovas, Remy Dulery, Franck Morschhauser, Sophie Caillat-Zucman, Roch Houot, Steven Le Gouill
Journal: Blood (2021)
Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain
Authors: Paolo F. Caimi, Armin Ghobadi, Jane Reese, Benjamin Tomlinson, Folashade Otegbeye, Julie K Ritchey, Tabatha Trummer, Jennifer Schiavone, Kayla Zamborsky, Linda G Eissenberg, Julia Hollaway, Dina Schneider, Kristen Bakalarz, Kirsten M Boughan, Leland Metheny, Seema Patel, Erin Galloway, Molly Gallogly, Winfried Krueger, Michael Kadan, Gabriela Pacheco Sanchez, Ashish Sharma, David Wald, Brenda W. Cooper, John F. DiPersio, Rafick Sekaly, Rimas J Orentas, Boro Dropulic, Marcos J.G. de Lima
Journal: Blood (2021)
Sustainability in skin cancer surgery
Authors: H. Jabouri, R.A. Abbott
Journal: British Journal of Dermatology (2021)

Carbon emissions ascribed to medical instruments account for one of the largest proportions of the NHS carbon footprint.1 Our aim was to evaluate the sustainable value of the main types of theatre packs used for skin surgery (single-use and reusable) based on their economic, environmental, and social sustainability, and determine which is more sustainable for long-term use.
Guiding the Standardization in Acute Leukemia Service Delivery through the Development of Organizational Requirements
Authors: Cassandra McKay, C. Tom Kouroukis, Sherrie Hertz, Rena J. Buckstein, Kardi Kennedy, Lia Kutzscher, Janet MacEachern, Mary Catherine McCann, Mitchell Sabloff, Karen Yee, Suzanna Apostolovski, Amanda Wong, Christopher Bredeson
Journal: Blood (2021)
A Systematic Review and Meta-Analysis Comparing Type I and II FLT3 Inhibitors in Relapsed/ Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Authors: Mai M M Aly, Mahesh Swaminathan, Katherine G. Akers, Seongho Kim, Harry Ramos, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian
Journal: Blood (2021)
Abstract 9429: The Impact of Hypo-Attenuated Leaflet Thickening on Valvular Haemodynamics and Structural Valve Deterioration Following Transcatheter Aortic Valve Replacement
Authors: Hashrul Rashid
Journal: Circulation (2021)

Introduction: Hypo-attenuated leaflet thickening (HALT) has been described following transcatheter aortic valve replacement (TAVR). It is unclear if HALT impacts prosthetic haemodynamics or predicts structural valve deterioration (SVD). Hypothesis: HALT predicts SVD. Methods: We prospectively evaluated 186 patients who had undergone TAVR with 320-slice CT imaging for the presence of HALT, defined as hypo-attenuation of bioprosthetic leaflets. HALT depth (thickness) was the greatest depth in the sagittal view and HALT area was the greatest area in the axial view. SVD was defined as at least one of mean gradient ≥20 mmHg, increase in gradient ≥10 mmHg from baseline and at least moderate valvular regurgitation. Echocardiograms at discharge, one month and annually were assessed by cardiologists blinded to HALT status. Results: LT prevalence was 17.7% at a median CT scan of 6 weeks (IQR 4-12). SVD occurred in 8.6% at a median follow-up of 2 years (IQR 1-3); two required valve re-intervention, five required anticoagulation that reversed moderate-severe gradient and nine had mild-moderate gradient that were closely monitored. Patients with HALT were more likely to develop SVD (39.3% vs 1.9%, p&lt;0.01), repeat valve replacement (6.1% vs 0%, p = 0.03) and higher valvular gradients throughout follow-up (up to 3-years). HALT affected 1 leaflet in 17 cases, 2 leaflets in 13 cases and 3 leaflets in 3 cases. Patients with HALT had a median cumulative thickness of 2.9 mm (IQR 1.9-4.7) and a median area of 64.2 mm2(IQR 40.9-91.6). Threshold for the occurrence of SVD with HALT characteristics were cumulative depth of 2.4 mm (Spec. 94.1%, Sens. 75.0%, AUC=0.87) and cumulative area of 28 mm2 (Spec. 92.2%, Sens. 81.3%, AUC=0.86). Conclusions: HALT was associated with SVD, repeat valve intervention and higher valvular gradients following TAVR. HALT depth and area were strong predictors of SVD. CT following TAVR may determine patients at-risk of SVD.
Cognitive impairment and World Trade Centre-related exposures
Authors: Sean A. P. Clouston, Charles B. Hall, Minos Kritikos, David A. Bennett, Steven DeKosky, Jerri Edwards, Caleb Finch, William C. Kreisl, Michelle Mielke, Elaine R. Peskind, Murray Raskind, Marcus Richards, Richard P. Sloan, Avron Spiro, Neil Vasdev, Robert Brackbill, Mark Farfel, Megan Horton, Sandra Lowe, Roberto G. Lucchini, David Prezant, Joan Reibman, Rebecca Rosen, Kacie Seil, Rachel Zeig-Owens, Yael Deri, Erica D. Diminich, Bernadette A. Fausto, Sam Gandy, Mary Sano, Evelyn J. Bromet, Benjamin J. Luft
Journal: Nature Reviews Neurology (2021)
Removal of a large jejunal laterally spreading tumor nongranular type by endoscopic submucosal dissection
Authors: Kengo Kasuga, Toshio Uraoka, Takashi Negishi, Keigo Sato, Hirohito Tanaka, Hiroko Hosaka, Shiko Kuribayashi
Journal: Endoscopy (2021)

Although endoscopic submucosal dissection (ESD) is widely performed for the resection of superficial gastrointestinal neoplasms, performing ESD for jejunal lesions is challenging because of the thin muscularis propria and inaccessibility or insufficient scope maneuverability around the lesion. Thus, few reports of ESD for jejunal lesions have been published [1]. Here, we report the case of a large jejunal laterally spreading tumor nongranular type (LST-NG) that was successfully treated with ESD ([Video 1]).
Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe – is the precautionary principle applicable?
Authors: Lucas Wiessing, Eleni Kalamara, Jack Stone, Peyman Altan, Luk Van Baelen, Anastasios Fotiou, D’Jamila Garcia, Joao Goulao, Bruno Guarita, Vivian Hope, Marie Jauffret-Roustide, Lina Jurgelaitienė, Martin Kåberg, Adeeba Kamarulzaman, Liis Lemsalu, Anda Kivite-Urtane, Branko Kolarić, Linda Montanari, Magdalena Rosińska, Lavinius Sava, Ilonka Horváth, Thomas Seyler, Vana Sypsa, Anna Tarján, Ioanna Yiasemi, Ruth Zimmermann, Marica Ferri, Kate Dolan, Anneli Uusküla, Peter T Vickerman
Journal: Eurosurveillance (2021)
Gut Microbiota Role in Response to Checkpoint Inhibitor Treatment in Patients with Relapsed/Refractory B-Cell Hodgkin Lymphoma: The MICRO-Linf Study
Authors: Beatrice Casadei, Serafina Guadagnuolo, Monica Barone, Silvia Turroni, Lisa Argnani, Patrizia Brigidi, Pier Luigi Zinzani
Journal: Blood (2021)
Learn-Morph-Infer: A new way of solving the inverse problem for brain tumor modeling
Authors: Ivan Ezhov, Kevin Scibilia, Katharina Franitza, Felix Steinbauer, Suprosanna Shit, Lucas Zimmer, Jana Lipkova, Florian Kofler, Johannes C. Paetzold, Luca Canalini, Diana Waldmannstetter, Martin J. Menten, Marie Metz, Benedikt Wiestler, Bjoern Menze
Journal: Medical Image Analysis (2022)
Abstract 15945: Mesenchymal Stem Cell-Derived Exosomes Mediate Myocardial Postconditioning Against Ischemia/Reperfusion Injury
Authors: Thomas L Lynch, Lauren Haar, Yang Wang, Qing Miao, Gina Kuffel, Michael J Zilliox, W. K Jones
Journal: Circulation (2018)

Introduction: Mesenchymal stem cell (MSC)-derived exosomes are membraneous extracellular vesicles that have been demonstrated to be paracrine mediators of cardioprotection against ischemia/reperfus...
PDE9 Inhibition By IMR-687 Improves Markers of Beta-Thalassemia in the Hbb th1/th1 Experimental Mouse Model
Authors: Thiago Trovati Maciel, Caroline Carvalho, Rachel Rignault, Slimane Allali, Biree Andemariam, Jennifer Isler OCain, Rahul Ballal
Journal: Blood (2021)
High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Authors: Junfang Yang, Xian Zhang, Ying Liu, Xiao Yang, Hui Wang, Lin Wang, Jianqiang Li, Peihua Lu
Journal: Blood (2021)
Evaluation of Placentation and the Role of the Aryl Hydrocarbon Receptor Pathway in a Rat Model of Dioxin Exposure
Authors: Khursheed Iqbal, Stephen H. Pierce, Keisuke Kozai, Pramod Dhakal, Regan L. Scott, Katherine F. Roby, Carrie A. Vyhlidal, Michael J. Soares
Journal: Environmental Health Perspectives (2021)

Our environment is replete with chemicals that can affect embryonic and extraembryonic development. Dioxins, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), are compounds affecting development through the aryl hydrocarbon receptor (AHR).The purpose of this investigation was to examine the effects of TCDD exposure on pregnancy and placentation and to evaluate roles for AHR and cytochrome P450 1A1 (CYP1A1) in TCDD action.Actions of TCDD were examined in wild-type and genome-edited rat models. Placenta phenotyping was assessed using morphological, biochemical, and molecular analyses.TCDD exposures were shown to result in placental adaptations and at higher doses, pregnancy termination. Deep intrauterine endovascular trophoblast cell invasion was a prominent placentation site adaptation to TCDD. TCDD-mediated placental adaptations were dependent upon maternal AHR signaling but not upon placental or fetal AHR signaling nor the presence of a prominent AHR target, CYP1A1. At the placentation site, TCDD activated AHR signaling within endothelial cells but not trophoblast cells. Immune and trophoblast cell behaviors at the uterine-placental interface were guided by the actions of TCDD on endothelial cells.We identified an AHR regulatory pathway in rats activated by dioxin affecting uterine and trophoblast cell dynamics and the formation of the hemochorial placenta. https://doi.org/10.1289/EHP9256.
First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)
Authors: Liana Nikolaenko, Carolyn Mulroney, Peter A. Riedell, Ian W. Flinn, Jose Carlos Cruz, Rakhee Vaidya, Koen van Besien, Michael Emde, Vadim Klyushnichenko, Jonathan Strauss, Eduardo Laborda, Jing Li, Mohit Trikha, Peter G. Schultz, Travis S Young
Journal: Blood (2021)
춘계학술대회 발표 : 포스터전시 ; 알코올성 간경변증 환자에서 대량 복수 천자 후 엉덩휘돌이동맥과 아랫배벽동맥의 거짓 동맥류에서 발생한 급성 복강 내 출혈 1예
Authors: 서승철, 엄민식, 박원우, 이보라, 허진국, 이종성, 김성은, 문정섭, 김유선, 이정환, 류수형
Journal: Clinical and Molecular Hepatology (2006)
Promising Real World Survival Data in Adult-Onset Langerhans Cell Histiocytosis: An Australasian Lymphoma Alliance 20 Year Retrospective Study
Authors: Georgia Mills, John Moore, Edward Cliff, Chun Yew Fong, Sarah Mangalasseril, Campbell Tiley, Michael Gilbertson, Matthew Ku, Ali Bazargan, Michelle Bryson, Monique Menzies Wojtowicz, Nagendra Prasad Sungala, Ilona Cunningham, Catherine Tang, Nada Hamad
Journal: Blood (2021)
Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial
Authors: Anna Sureda, Ana Pilar González, Javier Núñez, Javier Briones, Fátima De la Cruz, Domingo Domenech Eva, Francisca Maria Hernandez, María José Terol, Elena Amutio, Raul Cordoba, Carmen Martínez, Miriam Moreno, Antonia Rodriguez Izquierdo, Raquel Del Campo, Richard Greil, Samuel Romero, Ramón Garcia-Sanz
Journal: Blood (2021)